Previous 10 | Next 10 |
2023-03-06 17:35:33 ET Major earnings expected after the bell on Tuesday include: CrowdStrike Holdings ( CRWD ) Stitch Fix ( SFIX ) Cherry Hill Mortgage Investment Corporation ( CHMI ) Yext ( YEXT ) W&T Offshore ( WTI ) For further details...
2023-03-06 17:16:01 ET The following slide deck was published by CTI BioPharma Corp. in conjunction with their 2022 Q4 earnings call. For further details see: CTI BioPharma Corp. 2022 Q4 - Results - Earnings Call Presentation
2023-03-06 13:57:05 ET CTI BioPharma Corp. (CTIC) Q4 2022 Earnings Conference Call March 06, 2023 8:30 AM ET Company Participants Remy Bernarda – Investor Relations Adam Craig – President, Chief Executive Officer and Interim Chief Medical Officer Da...
2023-03-06 06:31:37 ET CTI BioPharma press release ( NASDAQ: CTIC ): Q4 GAAP EPS of -$0.14 misses by $0.05 . Revenue of $21.08M misses by $2.42M . As of December 31, 2022, cash, cash equivalents and short-term investments totaled $79.9 million, compared to $65....
CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire – Growing physician awareness and usage of VONJO ® (pacritinib) drove quarterly double-digit revenue growth – – VONJO ® net product revenue exce...
CTI BioPharma to Present at the 43rd Annual Cowen Health Care Conference PR Newswire SEATTLE , March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targe...
CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023 PR Newswire SEATTLE , Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company f...
CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023 PR Newswire SEATTLE , Feb. 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following i...
Summary CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40% growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTIC’s Vonjo (Pacritinib) is a differentiated late-stage JAK2/IRAK4/FLT3/CSF1R inhibitor for the treat...
Summary Today, we put CTI BioPharma in the spotlight for the first time since the first quarter of 2021. The company's primary asset Vonjo was approved by the FDA in March of 2022 and appears to be gaining significant sales traction. An updated investment analysis on CTI BioPharma f...
News, Short Squeeze, Breakout and More Instantly...
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders PR Newswire SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization ...
Shares of CTI BioPharma Corp. (NASDAQ: CTIC) traded at a new 52-week high today and are currently trading at $8.99. So far today, approximately 1.79M shares have been exchanged, as compared to an average 30-day volume of 10.16M shares. CTI BioPharma Corp., a biopharmaceutical company, focuses...
NEW YORK, NY / ACCESSWIRE / May 16, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Franchise Group, Inc. (NASDAQ: FRG)'s ...